These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19755606)

  • 1. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions.
    Shammas A; Lim R; Charron M
    Radiographics; 2009; 29(5):1467-86. PubMed ID: 19755606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography/computed tomography potential pitfalls and artifacts.
    Wang X; Koch S
    Curr Probl Diagn Radiol; 2009; 38(4):156-69. PubMed ID: 19464586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.
    Israel O; Yefremov N; Bar-Shalom R; Kagana O; Frenkel A; Keidar Z; Fischer D
    J Nucl Med; 2005 May; 46(5):758-62. PubMed ID: 15872347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET and PET/CT in pediatric oncology.
    Jadvar H; Connolly LP; Fahey FH; Shulkin BL
    Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
    Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
    J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
    Jerushalmi J; Frenkel A; Bar-Shalom R; Khoury J; Israel O
    J Nucl Med; 2009 Jun; 50(6):849-53. PubMed ID: 19443604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
    Yamaguchi T; Ueda O; Hara H; Sakai H; Kida T; Suzuki K; Adachi S; Ishii K
    Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bowel hot spots at PET-CT.
    Prabhakar HB; Sahani DV; Fischman AJ; Mueller PR; Blake MA
    Radiographics; 2007; 27(1):145-59. PubMed ID: 17235004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body 18F-FDG PET/CT in the presence of truncation artifacts.
    Beyer T; Bockisch A; Kühl H; Martinez MJ
    J Nucl Med; 2006 Jan; 47(1):91-9. PubMed ID: 16391192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation.
    Wykrzykowska J; Lehman S; Williams G; Parker JA; Palmer MR; Varkey S; Kolodny G; Laham R
    J Nucl Med; 2009 Apr; 50(4):563-8. PubMed ID: 19289431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.
    Yeung HW; Grewal RK; Gonen M; Schöder H; Larson SM
    J Nucl Med; 2003 Nov; 44(11):1789-96. PubMed ID: 14602861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
    Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
    J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
    Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
    J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.